Vanguard Asset Management’s Mineralys Therapeutics MLYS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.14M Buy
45,261
+6,074
+16% +$165K ﹤0.01% 1801
2026
Q2
$1.06M Buy
39,187
+9,934
+34% +$273K ﹤0.01% 1850
2026
Q1
$792K Buy
+29,253
New +$858K ﹤0.01% 1891

Other funds holding MLYS

Vanguard Asset Management's MLYS Position: Q3 2026 in Review

Vanguard Asset Management increased its Mineralys Therapeutics (MLYS) stake by 16% in Q3 2026, buying an estimated $165K and bringing the position to 45,261 shares worth $1.14M. The position accounts for ﹤0.01% of the portfolio, ranked #1801.

Vanguard Asset Management first reported a position in MLYS in Q1 2026 and has held it in 3 quarters since. 219 funds tracked by Wall St. Rank hold MLYS as of Q3 2026.

  • Vanguard Asset Management held 45,261 shares of Mineralys Therapeutics worth $1.14M as of Q3 2026.
  • Vanguard Asset Management bought 6,074 Mineralys Therapeutics shares in Q3 2026, an estimated $165K.
  • Mineralys Therapeutics made up ﹤0.01% of Vanguard Asset Management's portfolio in Q3 2026, its #1801 holding.
  • Vanguard Asset Management first reported a position in Mineralys Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 219 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q3 2026.

Based on Vanguard Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.